Patents by Inventor Eric Voight

Eric Voight has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220251123
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.
    Type: Application
    Filed: September 2, 2021
    Publication date: August 11, 2022
    Inventors: Kathleen Ann Martin, Carmela Sidrauski, Michael J. Dart, Jennifer M. Frost, Yunsong Tong, Xiangdong Xu, Lei Shi, Kathleen Murauski, Marina Pliushchev, Brian S. Brown, Eric Voight, John T. Randolph
  • Patent number: 11149043
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.
    Type: Grant
    Filed: April 9, 2021
    Date of Patent: October 19, 2021
    Assignees: Calico Life Sciences LLC, AbbVie Inc.
    Inventors: Michael J. Dart, Jennifer M. Frost, Yunsong Tong, Xiangdong Xu, Lei Shi, Kathleen Murauski, Marina Pliushchev, Brian S. Brown, Eric Voight, John T. Randolph
  • Publication number: 20210300863
    Abstract: A method of preparing a compound of Formula (I) comprising reacting the compound of Formula (A) with a base and a compound of Formula (B) to yield a compound of Formula (C).
    Type: Application
    Filed: August 1, 2019
    Publication date: September 30, 2021
    Applicant: Intervet Inc.
    Inventors: Eric Voight, Christophe Pierre Alain Chassaing, Hans Peter Niedermann, Stephan Veit, Claudia Scheipers
  • Publication number: 20210230195
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.
    Type: Application
    Filed: April 9, 2021
    Publication date: July 29, 2021
    Inventors: Kathleen Ann Martin, Carmela Sidrauski, Michael J. Dart, Jennifer M. Frost, Yunsong Tong, Xiangdong Xu, Lei Shi, Kathleen Murauski, Marina Pliushchev, Brian S. Brown, Eric Voight, John T. Randolph
  • Publication number: 20190358214
    Abstract: The present invention features compositions and methods for the treatment of HCV infection. In one embodiment, the compositions of the invention comprise (1) Compound 1 or a pharmaceutically acceptable salt thereof, and (2) Compound 2a or a pharmaceutically acceptable salt thereof. In another embodiment, the compositions of the invention comprise (1) Compound 1 or a pharmaceutically acceptable salt thereof, and (2) a prodrug of Compound 2a (e.g., one of Compounds 2b-2k or Examples 3-1 to 3-10) or a pharmaceutically acceptable salt of said prodrug.
    Type: Application
    Filed: November 13, 2017
    Publication date: November 28, 2019
    Applicant: AbbVie Inc.
    Inventors: Brian Brown, Hui-Ju Chen, David DeGoey, Geoff Halvorsen, John Hartung, Howard R. Heyman, Nathan Ide, Dale Kempf, Allen C. Krueger, Tao Li, Tongmei Li, Steven R. Martinez, Christopher C. Marvin, John T. Randolph, Eric Voight, Rolf Wagner, Jaclyn Chau
  • Publication number: 20190224220
    Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
    Type: Application
    Filed: April 20, 2017
    Publication date: July 25, 2019
    Applicant: AbbVie Inc.
    Inventors: Philip R. Kym, Eric Voight
  • Publication number: 20190135827
    Abstract: The present invention provides for compounds of formula (I) wherein X, Y, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    Type: Application
    Filed: January 8, 2019
    Publication date: May 9, 2019
    Inventors: Robert J. Altenbach, Andrew Bogdan, Marlon D. Cowart, William Rameshchandra Krishna Esmieu, Gregory A. Gfesser, Stephen N. Greszler, John R. Koenig, Philip R. Kym, Bo Liu, Karine Fabienne Malagu, Sachin V. Patel, Marc J. Scanio, Xenia B. Searle, Eric Voight, Xueqing Wang, Ming C. Yeung
  • Publication number: 20190127356
    Abstract: The invention provides for compounds of formula (I) wherein R1, X, Y, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, m, and R? have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    Type: Application
    Filed: December 19, 2018
    Publication date: May 2, 2019
    Inventors: Robert J. Altenbach, Andrew Bogdan, Stephen N. Greszler, John R. Koenig, Philip R. Kym, Bo Liu, Xenia B. Searle, Eric Voight, Xueqing Wang, Ming C. Yeung
  • Patent number: 10053474
    Abstract: The present invention features compounds effective in inhibiting active against Hepatitis C virus (“HCV”) polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: August 21, 2018
    Assignee: AbbVie Inc.
    Inventors: Jaclyn Chau, Hui-Ju J. Chen, David A. DeGoey, John Hartung, Nathan Ide, Vikram Kalthod, Allan C. Krueger, Yi-Yin Ku, Tongmei Li, John T. Randolph, Rolf Wagner, Geoff T. Halvorsen, Christopher C. Marvin, Eric Voight, Brian S. Brown, Steven R. Martinez, Anurupa Shrestha, Howard R. Heyman
  • Publication number: 20180037587
    Abstract: The present invention provides for compounds of formula (I) wherein X, Y, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    Type: Application
    Filed: October 17, 2017
    Publication date: February 8, 2018
    Inventors: Robert J. Altenbach, Andrew Bogdan, Marlon D. Cowart, William Rameshchandra Krishna Esmieu, Gregory A. Gfesser, Stephen N. Greszler, John R. Koenig, Philip R. Kym, Bo Liu, Karine Fabienne Malagu, Sachin V. Patel, Marc J. Scanio, Xenia B. Searle, Eric Voight, Xeuqing Wang, Ming C. Yeung
  • Publication number: 20180022763
    Abstract: The present invention features compounds effective in inhibiting active against Hepatitis C virus (“HCV”) polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Type: Application
    Filed: May 5, 2017
    Publication date: January 25, 2018
    Applicant: AbbVie Inc.
    Inventors: Jaclyn Chau, Hui-Ju J. Chen, David A. DeGoey, John Hartung, Nathan Ide, Vikram Kalthod, Allan C. Krueger, Yi-Yin Ku, Tongmei Li, John T. Randolph, Rolf Wagner, Geoff T. Halvorsen, Christopher C. Marvin, Eric Voight, Brian S. Brown, Steven R. Martinez, Anurupa Shrestha, Howard R. Heyman
  • Patent number: 9840513
    Abstract: The present invention provides for compounds of formula (I) wherein X, Y, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: December 12, 2017
    Assignees: AbbVie S.á.r.l., Galapagos NV
    Inventors: Robert J. Altenbach, Andrew Bogdan, Marlon D. Cowart, William Ramesh Esmieu, Gregory A. Gfesser, Stephen N. Greszler, John R. Koenig, Philip R. Kym, Bo Liu, Karine Fabienne Malagu, Sachin V. Patel, Marc J. Scanio, Xenia B. Searle, Eric Voight, Xeuquing Wang, Ming C. Yeung
  • Publication number: 20170190693
    Abstract: The invention provides for compounds of formula (I) wherein R1, X, Y, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, m, and R? have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    Type: Application
    Filed: March 23, 2017
    Publication date: July 6, 2017
    Inventors: Robert J. Altenbach, Andrew Bogdan, Stephen N. Greszler, John R. Koenig, Philip R. Kym, Bo Liu, Xenia B. Searle, Eric Voight, Xueqing Wang, Ming C. Yeung
  • Patent number: 9676797
    Abstract: The present invention features compounds effective in inhibiting active against Hepatitis C virus (“HCV”) polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: June 13, 2017
    Assignee: AbbVie Inc.
    Inventors: Hui-Ju J. Chen, David A. DeGoey, John Hartung, Nathan Ide, Vikram Kalthod, Allan C. Krueger, Yi-Yin Ku, Tongmei Li, John T. Randolph, Rolf Wagner, Jaclyn Chau, Geoff T. Halvorsen, Christopher C. Marvin, Eric Voight
  • Patent number: 9642831
    Abstract: The invention provides for compounds of formula (I) wherein R1, X, Y, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, m, and R? have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: May 9, 2017
    Assignees: AbbVie S.á.r.l., Galapagos NV
    Inventors: Robert J. Altenbach, Andrew Bogdan, Stephen N. Greszler, John R. Koenig, Philip R. Kym, Bo Liu, Xenia B. Searle, Eric Voight, Xueqing Wang, Ming C. Yeung
  • Publication number: 20170057981
    Abstract: The present invention features compounds effective in inhibiting active against Hepatitis C virus (“HCV”) polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Type: Application
    Filed: September 1, 2016
    Publication date: March 2, 2017
    Applicant: AbbVie Inc.
    Inventors: Hui-Ju J. Chen, David A. DeGoey, John Hartung, Nathan Ide, Vikram Kalthod, Allan C. Krueger, Yi-Yin Ku, Tongmei Li, John T. Randolph, Rolf Wagner, Jaclyn Chau, Geoff T. Halvorsen, Christopher C. Marvin, Eric Voight
  • Publication number: 20170015675
    Abstract: The present invention provides for compounds of formula (I) wherein X, Y, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    Type: Application
    Filed: July 8, 2016
    Publication date: January 19, 2017
    Inventors: Robert J. Altenbach, Andrew Bogdan, Marlon D. Cowart, William Ramesh Esmieu, Gregory A. Gfesser, Stephen N. Greszler, John R. Koenig, Philip R. Kym, Bo Liu, Karine Fabienne Malagu, Sachin V. Patel, Marc J. Scanio, Xenia B. Searle, Eric Voight, Xeuqing Wang, Ming C. Yeung
  • Publication number: 20160120841
    Abstract: The invention provides for compounds of formula (I) wherein R1, X, Y, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, m, and R? have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    Type: Application
    Filed: October 28, 2015
    Publication date: May 5, 2016
    Inventors: Philip R. Kym, Xueqing Wang, Xenia B. Searle, Bo Liu, Ming C. Yeung, Robert J. Altenbach, Eric Voight, Andrew Bogdan, John R. Koenig
  • Patent number: 7998993
    Abstract: Compounds of formula (I) wherein R1, R2, R4, and W are defined in the description are TRPV 1 antagonists with CNS penetration. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Grant
    Filed: October 23, 2008
    Date of Patent: August 16, 2011
    Assignee: Abbott Laboratories
    Inventors: Richard J. Perner, John R. Koenig, Stanley DiDomenico, Jr., Erol K. Bayburt, Jerome F. Daanen, Arthur Gomtsyan, Michael E. Kort, Philip R. Kym, Robert G. Schmidt, Anil Vasudevan, Eric Voight
  • Publication number: 20090124666
    Abstract: Compounds of formula (I) wherein R1, R2, R4, and W are defined in the description are TRPV 1 antagonists with CNS penetration. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Application
    Filed: October 23, 2008
    Publication date: May 14, 2009
    Applicant: ABBOTT LABORATORIES
    Inventors: Richard J. Perner, John R. Koenig, Stanley Didomenico, JR., Erol K. Bayburt, Jerome F. Daanen, Arthur Gomtsyan, Michael E. Kort, Philip R. Kym, Robert G. Schmidt, Anil Vasudevan, Eric Voight